Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/18—Growth factors; Growth regulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7088—Compounds having three or more nucleosides or nucleotides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• This invention relates to the use of polyp eptides derived from the sequence of the IGF -I splice variant MGF and polynucleotides encoding such polypeptides in the prevention of myocardial damage following ischemia and/or mechanical overload.
• Ischemia occurs when an artery supplying oxygenated blood to a muscle or other organ becomes occluded. This diminishes the ability of the affected organ to function and may involve cell death in the area whose blood supply is reduced.
• Ischemic heart disease is a major cause of death. Even in those patients who survive a heart attack, the prospects of an active lifestyle are severely reduced due to the loss of cardiac muscle. Cardiac muscle, like skeletal muscle and the central nervous system, is a post-mitotic tissue. As there is virtually no cell replacement throughout life, there has to be an effective ongoing local repair mechanism. Local physical and free radical damage occurs even in healthy tissues and has to be repaired; otherwise the cell undergoes cell death that results in a permanent functional deficit.
• ischemia can result from an obstruction of the coronary arteries. This leads to cardiomyocytes in certain areas becoming deprived of blood and thus oxygen. They then commence to die. This means increased mechanical strain on the surviving myocardiocytes in the area becoming damaged, which also leads to cell death. Thus, cell death occurs both as a result of oxygen deprivation and as a result of undue mechanical strain.
• the region of cell death, or necrosis, is known as an infarct.
• Mammalian IGF -I polypeptides have a number of isoforms, which arise as a result of alternative mRNA splicing. Broadly, there are two types of isoform, liver-type isoforms and non-liver-type ones. Liver-type isoforms may be expressed in the liver or elsewhere but, if expressed elsewhere, are equivalent to those expressed in the liver. They have a systemic action and are the main isoforms in mammals. Non- liver-type isoforms are less common and some are believed to have an autocrine/ paracrine action. The MGF isoform of the invention is of the latter type.
• IGF-I splice variants are based on the liver isoforms (Chew et al, 1995) and has not fully evolved to take into account those produced by non-liver tissues. The latter are controlled to some extent by a different promoter (promoter 1) to the liver IGF-I isoforms, which respond to hormones and are under the control of promoter 2.
• exons 1 and 2 are alternative leader exons with distinct transcription start sites which are differentially spliced to common exon 3.
• Exons 3 and 4 code for the mature IGF-I peptide (B, C, A and D domains) as well as the first 16 amino acids of the E domain.
• Exons 5 and 6 each encode an alternative part of a distinct extension peptide, the E domain. This is followed by the termination codons of precursor IGF-I, 3' untranslated regions and poly(A) addition signal sites.
• MGF Mechano Growth Factor
• MGF (Figure 1; Yang et al, 1996; McKoy et al, 1999) has exons 4, 5 and 6 whilst the muscle-expressed liver-type IGF-I has exons 4 and 6.
• the other two splice variants found in human muscle have similar sequences to the liver systemic type of IGF-I.
• human MGF has a 49 base pair insert (E domain) which changes its reading frame at the carboxy end.
• MGF for the treatment of disorders of skeletal muscle, notably muscular dystrophy (WO97/33997; US Patent No. 6,221,842; Yang et al, 1996; McKoy et al, 1999), for the treatment of neurological disorders (WO01/136483) and for nerve repair (WO01/85781).
• myocardial injury that can occur often result in myocyte cell death (apoptosis) resulting in the loss of functioning myocytes.
• the remaining healthy myocytes generally increase in size in order to maintain cardiac output. This again leads to a hypertrophic state and can also develop to the point when it becomes a pathological condition.
• L. IGF-I liver-type IGF-I
• GH growth hormone
• 6,221,842 also mentions the possibility of prevention of cardiac disorders, diseases where promotion of cardiac muscle protein synthesis is a beneficial treatment, cardiomyopathies, acute heart failure or acute insult including myocarditis or myocardial infarction, and improving cardiac output by increasing heart/volume; but does not provide experimental findings linking MGF to cardiac, as opposed to skeletal, muscle.
• MGF is strongly expressed in the infarcted area following ischemia in rat and sheep heart.
• MGF expression coincides with the immediate recovery stage following mechanical overload and transient ischemia. MGF expression is therefore more rapid than L-IGF-I expression.
• MGF expression is induced in cardiac myocytes undergoing apoptosis, that stable transfection of the cardiac-like cell line H9C2 with MGF prevents apoptosis and obtained evidence that MGF induces a hypertrophic phenotype in myocytes in vitro.
• MGF myofilaments but not thin filament proteins. This acts to dedifferentiate the myocyte.
• MGF expression results in remodeling of the infarcted region, i.e. that by dedifferentiating the myocyte, MGF facilitates the repair process.
• E domain (part of exon 4) is important in cardiac muscle for local tissue repair, although this does not appear to involve stem cell activation as cardiac muscle is not believed to possess stem cells.
• Our data therefore suggest that the E domain insert in MGF not only changes the reading frame of the C-terminal end of the peptide from that of L.IGF-I but also that the E domain may have a separate function in cellular cardiomyocyte repair.
• Rapid administration of an MGF polypeptide after a heart attack is particularly desirable, and longer term treatment can also be effected, especially by delivering an polynucleotide encoding an MGF polypeptide to maintain levels of MGF in the cardiac muscle after initial administration of the polypeptide.
• the invention provides :
• MGF Mechano Growth Factor
• a product comprising an MGF polypeptide and a polynucleotide encoding an MGF polypeptide for simultaneous, separate or sequential use in the prevention of myocardial damage in response to ischemia or mechanical overload of the heart;
• MGF Mechano Growth Factor
• This Figure shows the exon sequence of the IGF-I splice variants expressed in human skeletal muscle. Two of these have similar sequences to the systemic IGF -Is produced by the liver. Human MGF transcript has a 49 base (52 base in rat and rabbit) insert in the E domain which alters the reading frame and hence the C-terminal end of the peptide differs from that of the other splice variants.
• FIG. 1 Induction of MGF expression in aortic banded hearts
• mice (3) were banded for 7 days following which MGF expression was assayed using quantitative real time RT-PCR in total RNA extracted form the heart.
• A. Results of the RT-PCR reaction run on agarose gels for MGF and IGF.
• FIG. 3 Induction of the hypertrophic marker genes with overexpression of MGF
• FIG. 5 MGF expression in cardiac myocytes under apoptotic conditions
• Figure 6 Induction of apoptosis in cardiac cell line transfected with MGF and L.IGF
• Cells were stably transfected with cDNA encoding MGF and L.IGF-I and selected by resistance to antibiotic using standard techniques. Once clones were identified, these were isolated and expanded as separate lines of cells. Control cells, which had not been transfected, plus stable MGF and L.IGF-I clones were plated out and treated for 24 hours with 0.3M Sorbitol. Following treatment, DNA was extracted and subjected to electrophoresis (1% agarose) to determine if DNA fragmentation had occurred. Lanes 1 and 5 are DNA markers (lOObp and IkB respectively). Lane 2, control H9C2 cells after 24 hour sorbitol. Lane 3, MGF transfected H9C2 cells after 24 hour sorbitol.
• Lane 4 IGF transfected H9C2 cells after 24 hour sorbitol. It can be clearly seen that DNA fragmentation takes place in the control cells which are undergoing apoptosis, whereas cells overexpressing either the MGF or L.IGF-I genes do not undergo apoptosis.
• Figure 7 cDNA and amino acid sequence of human MGF, showing its exon structure.
• Figure 8 cDNA and amino acid sequence of rat MGF, showing its exon structure.
• Figure 9 cDNA and amino acid sequence of rabbit MGF, showing its exon structure.
• Figure 10 cDNA and amino acid sequence of human L.IGF-I, showing its exon structure.
• Figure 11 cDNA and amino acid sequence of rat L-IGF-I, showing its exon structure.
• Figure 12 cDNA and amino acid sequence of rabbit L-IGF-I, showing its exon structure.
• Figure 13 Sequence alignment, illustrating exon structure of human, rat and rabbit MGF and L-IGF-I, and highlighting similarities and differences.
• FIG. 14 Cardiac myocytes infected with MGF and IGF viruses for 24hrs
• FIG. 16 Cardiac myocytes infected for 48 hrs with the MGF and control GFP expressing virus
• Cells were counter stained with phalloidin and DAPI to visualize the myofilaments.
• Figure 17 Analysis of thick and thin filament expression with RT-PCR following 48hrs of MGF viral infection in cardiac myocytes
• Figure 18 Quantitative analysis of ⁇ MHC expression in cardiac myocytes following 48hrs of MGF viral infection.
• Figure 19 Mean percentage of damaged-regenerating muscle fibre area in relation to the whole muscle section in two damage models
• MGF stands for mechano-growth factor (cf. McKoy et al, 1999). As discussed above, MGF is an alternatively spliced variant of IGF-I. Liver-type IGF-I (L.IGF-I) comprises amino acids encoded by exons 4 and 6 whereas MGF comprises amino acids encoded by exons 4, 5 and 6. MGF also has an altered reading frame at its carboxy terminus as a result of a 49 (human) or 52 (rat, rabbit) bp insert in exon 5, and is smaller because it is not glycosylated. Chew et al (1995) and Yang et al (1996) did not use the term MGF, but rather IGF-I Ec, to define the 4-5-6 splice variant. The muscle isoform that has the Ec domain is now known as MGF (cf McKoy et al, 1999; WO01/136483; WO01/85781).
• an MGF polypeptide is understood to be any IGF-I polypeptide having the 4- 5-6 exon structure or being derived from an IGF-I polypeptide with the 4-5-6 exon structure and one or more of the functional properties of MGF described herein or already identified by the Inventors, e.g. as in WO97/33997 and/or WO01/136483 and/or WOO 1/85781.
• the exon structure of MGF in human, rat and rabbit is illustrated in Figures 7, 8 and 9 (SEQ ID NOs. 1/2, 3/4 and 5/6).
• the exon structure of human, rat and rabbit L.IGF-I is given in Figures 10, 11 and 12 (SEQ ID NOs. 9/10, 11/12 and 13/14), and a comparison between MGF and L.IGF-I is made in Figure 13.
• MGF polypeptides of the invention will have the reading frame which, in native MGF, is generated by the 49/52 bp insert mentioned above.
• MGF polypeptides of the invention will not be glycosylated. However, they may be glycosylated or partially glycosylated in some embodiments. By partially glycosylated is meant up to 10, 20, 30, 50, 70, 80, 90, 95 or 99% as much glycosylation as L.IGF-I, e.g. containing some, but not all, of L.IGF -I's glycosylation sites.
• the pattern of glycosylation may be the same as that of L.IGF-I in terms of the type and placement of sugars or it may be different.
• MGF polypeptides of the invention comprise sequences encoded by exons 3, 4, 5 and 6 or equivalent sequences.
• they may include exons 1 and/or 2, or equivalent sequences as well.
• they may also be shorter, e.g. comprising only sequences encoded by exons 5 and 6 or by exons 4, 5 and 6.
• MGF polypeptides of the invention may find their origins in any species that has 4-5- 6 spliced IGF-I.
• an MGF polypeptide of the invention may have the sequence of human MGF or represent a truncated form of human MGF.
• human MGF polypeptides are is generally preferred.
• MGF polypeptides having the sequence of an animal MGF may also be used, e.g. rat, rabbit, mouse, cow, sheep, goat, chicken, dog, cat MGF.
• the species origin of the MGF polypeptide used will be matched to the species of the subject to be treated.
• exons 3, 4, 5 and 6 of human MGF (IGF-I-Ec) (SEQ ID NO. 1/2, Figure 7), rat MGF (SEQ ID NO. 3/4, Figure 8) and rabbit MGF (IGF-I Eb) (SEQ ID NO. 5/6, Figure 9) are given below, together with their corresponding cDNA sequences.
• SEQ ID NOs. 1, 3 and 5 are the cDNAs;
• SEQ ID NOs. 2, 4 and 6 are the polypeptides.
• sequences of exons 3, 4 and 6 human SEQ ID NO. 9/10, Figure 10
• rat SEQ ID NO. 11/12, Figure 11
• rabbit SEQ ID NO.
• liver-type IGF-I L.IGF-I
• Polypeptides having the sequences of SEQ ID NOs. 2, 4 and 6 may be used in preferred embodiments of the invention.
• MGF polypeptides may have the functional properties identified by the Inventors in WO97/33997. In particular, they may have the ability to induce growth of skeletal muscle tissue. Similarly, as discussed herein, they may have the ability to upregulate protein synthesis needed for skeletal muscle repair and/or to activate satellite (stem) cells in skeletal muscle. Alternatively or additionally, MGF polypeptides of the invention may have the neurological properties previously identified by the Inventors in WOO 1/136483. Thus, they may have the capacity to effect motoneurone rescue.
• they may be able to reduce motoneurone loss following nerve avulsion by up to 20, 30, 40, 50, 60, 70, 80, 90, 95, 99 or 100% in a treated subject compared to an equivalent situation in a non-treated subject.
• Reduction of motoneurone loss by 70% or more, or 80% more (i.e. to 30% or less or 20%) or less) is preferred.
• the degree of rescue may be calculated using any suitable technique, e.g. a known technique such as Stereology.
• WO01/136483 which rely on measuring motoneurone rescue in response to facial nerve avulsion in rats, may be used.
• an MGF polypeptide of the invention will have the ability to prevent or limit myocardial damage following ischemia or mechanical overload by preventing cell death, or apoptosis, of the muscle cells of the myocardium.
• an MGF polypeptide of the invention will have the ability to completely prevent apoptosis in the area of cardiac muscle to which it is applied.
• apoptosis may also be only partially prevented, i.e. limited. Damage is limited if any reduction of damage is achieved compared to that which would have taken place without a treatment of the invention, e.g.
• ⁇ damage is reduced by 1%> or more, 5%> or more, 10%> or more, 20%> or more, 30%> or more, 50% or more, 70% or more, 80%> or more, 90%> or more, 95%> or more, 98% or more, or 99%> or more, as measured by the number or proportion of cells which die, or by the size of the area of muscle that loses function, or by the overall ability of the heart to pump blood.
• reduction of damage can be estimated in vivo by determining cardiac output, ejection fraction etc using minimally invasive methods. Markers such as creatine kinase and troponin T in the serum can also be assayed. These are the parameters used in clinical situations to determine the extent damage to the cardiac muscle following injury.
• the ability to prevent apoptosis may be measured by any suitable technique. For example, with reference to Example 4 and Figures 3 and 6, it may be measured by the ability to prevent apoptosis in a cardiac muscle cell or cardiac-like cell line, as indicated by DNA fragmentation. This may be assessed, in particular, in a cardiaclike cell line such as H9C2 stably transfected with a vector which expresses the MGF polypeptide.
• the ability to prevent aptosis, as indicated by DNA fragmentation may be tested by treating the cells with sorbitol or another agent that places the cells under osmotic stress for up to, e.g.
• An MGF polypeptide of the invention expressed in this way will typically reduce, preferably eliminate, DNA fragmentation under these conditions, as compared to an untransfected or sham-transfected (vector but no MGF coding sequence) after 6, 12 or 24 hours' sorbitol treatment.
• the absence of expression, or low expression, of genes that act as markers for apoptosis can also act as an indication of prevention of apoptosis.
• One suitable marker is the Bax gene.
• anti-apoptosic markers in MGF -transfected cells under apoptotic conditions can be taken as a sign that the polypeptide of the invention is preventing apoptosis.
• One suitable anti-apoptotic marker gene is Bcl2.
• the ability to prevent apoptosis may also be measured by reference to an MGF polypeptide's ability to prevent a reduction in cell number in myocyte cells in vitro.
• cells can be transfected with a vector encoding the MGF polypeptide, such that it is overexpressed. Then, cell counts in MGF-transfected and control cultures can be compared over time under apoptotic conditions.
• cells will die off less quickly in the MGF-transfected cultures, leaving greater proportion of the original number of cells in these cultures after, e.g. 24, 48 or 72 hours. For example up to 5% or more, 10% or more, 20% or more or 50% or more cells may remain in the MGF-transfected cultures after 24, 48 or 72 hours than in the control cultures.
• MGF polypeptides of the invention is the ability to induce a hypertrophic phenotype in cardiac muscle cells.
• this may be tested by assessing the ability to induce a hypertrophic phenotype in primary cardiac myocyte cultures in vitro.
• such cultures can be transfected with a vector, e.g. a plasmid, encoding the MGF polypeptide such that the polypeptide of the invention is overexpressed, and the ability to induce hypertrophic phenotype determined.
• a preferred method for determining this is to test for an increase in expression of ANF (Atrial Natriuretic Factor) and/or bMHC (Beta Myosin Heavy Chain).
• ANF is an embryonic marker gene that is upregulated in hypertrophic conditions.
• bMHC is an imporant contractile protein in muscle.
• MGF polypeptides having the sequence of naturally occurring MGFs are preferred.
• variant MGFs having the same basic 4-5-6 exon structure and properties may also be used.
• Polypeptides of the invention may be encoded by polynucleotides as described below.
• An MGF polypeptide of the invention may consist essentially of the amino acid sequence set out in SEQ ID NO..2, 4 or 6 or a substantially homologous sequence, or of a fragment of either of these sequences, as long as the functional properties of the invention are maintained.
• the naturally occurring amino acid sequences shown in SEQ ID NOs. 2, 4 and 6 are preferred.
• the polypeptides of the invention include homologues of the natural sequences, and fragments of the natural sequences and of their homologues, which have one or more of the functional properties of MGF, as defined herein.
• polypeptide of the invention may comprise:
• allelic variants (e) an allelic variant or species homologue of a sequence of (a).
• allelic variant will be a variant which occurs naturally and which will function in a substantially similar manner to the protein of SEQ ID NO. 2, 4 or 6 as defined above.
• a species homologue of the protein will be the equivalent protein which occurs naturally in another species.
• Such a homologue may occur in any species, preferably a mammalian species, for example a bovine, equine, ovine, feline or canine species; such as cow, horse, sheep or goat, cat, or dog; or in a rodent species other than rat (SEQ ID NO. 4) or rabbit (SEQ ID NO. 6), or in a primate species other than human (SEQ ID NO. 2).
• Non-mammalian MGFs for example piscine or avian MGFs, e.g. chicken MGF, are also MGFs of the invention.
• a homologue may exist as several allelic variants, and these will all be considered homologues of the protein of SEQ ID NO. 2, 4 or 6.
• Allelic variants and species homologues can be obtained by methods known in the art, e.g. by probing suitable cell source with a probe derived from SEQ ID NO. 1, 3 or 5. Clones obtained can be manipulated by conventional techniques to generate a polypeptide of the invention which can be produced by recombinant or synthetic techniques known per se.
• a polypeptide of the invention is preferably at least 70% homologous to the protein of SEQ ID NO. 2, 4 or 6 more preferably at least 80 or 90% and more preferably still at least 95, 97 or 99%> homologous thereto over a region of at least 20, preferably at least 30, for instance at least 40, 60 or 100 or more contiguous amino acids.
• Methods of measuring protein homology are well known in the art and it will be understood by those of skill in the art that in the present context, homology is calculated on the basis of amino acid identity (sometimes referred to as "hard homology"). Degrees of homology can be measured by well-known methods, as discussed herein for polynucleotide sequences.
• sequence of the polypeptides of SEQ ID NOs. 2, 4 and 6 and of the allelic variants and species homologues can be modified to provide further polypeptides of the invention.
• Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions. For example, a total of up to 1, 2, 5, 10 or 20 amino acids may be substituted over a length of 50, 100 or 200 amino acids in the polypeptides. For example, up to 20 amino acids substituted over any length of 50 amino acids.
• the modified polypeptide generally retains one or more of the functional properties of MGF, as defined herein. Conservative substitutions may be made, for example according to the following table. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other.
• Polypeptides of the invention also include fragments of the above-mentioned full length polypeptides and variants thereof, including fragments of the sequence set out in SEQ ID NOs. 2, 4 and 6.
• Suitable fragments will generally be at least about 20, e.g. at least 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids in size.
• Polypeptide fragments of the polypeptides of SEQ ID NOS. 2, 4 and 6 and allelic and species variants thereof may contain one or more (e.g. 2, 3, 5, 5 to 10 or more) substitutions, deletions or insertions, including conservative substitutions. Each substitution, insertion or deletion may be of any length, e.g. 1, 2, 3, 4, 5, 5 to 10 or 10 to 20 amino acids in length.
• fragments of the invention may comprise the amino acids encoded by exons 5 and 6 or 4, 5 and 6 of human, rat or rabbit DNA of SEQ ID NO . 1 , 3 or 5.
• the first amino aid of exon 4, Asn is partly encoded by exon 3 (1 nucleotide) and partly by exon 4 (2 nucleotides). It is preferred that said first amino acid be present, in a fragment of the invention.
• MGF polypeptides encoded by chimeric polynucleotide sequences of the invention may be used.
• Polypeptides of the invention may be in a substantially isolated form. It will be understood that the polypeptide may be mixed with carriers or diluents which will not interfere with the intended purpose of the polypeptide and still be regarded as substantially isolated.
• a polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 70%, e.g. more than 80, 90, 95, 98 or 99% of the polypeptide in the preparation is a polypeptide of the invention.
• Polypeptides of the invention may be provided in a form such that they are outside their natural cellular environment. Thus, they may be substantially isolated or purified, as discussed above, or in a cell which they do not occur in nature, e.g. a cell or other plant species, animals, yeast or bacteria.
• Polypeptides of the invention may be modified for example by the addition of Histidine residues or a T7 tag to assist their identification or purification or by the addition of a signal sequence to promote their secretion from a cell.
• a polypeptide of the invention may be labelled with a revealing label.
• the revealing label may be any suitable label which allows the polypeptide to be detected. Suitable labels include radioisotopes, e.g. 125 1, 35 S, enzymes, antibodies, polynucleotides and linkers such as biotin.
• Polypeptides of the invention may be chemically modified, e.g. post-translationally modified.
• they may comprise modified amino acid residues. They may also be glycosylated (see above), though MGF is not naturally glycosylated.
• modified polypeptides will be understood to be polypeptides of the invention.
• the effects of modifications to MGF's sequence can be tested by any suitable method.
• the binding properties and/or stability of variant MGFs can be tested by comparing them in vitro or in vivo to those of unmodified MGF.
• Polynucleotides of the invention encode polypeptides of the invention.
• Preferred polynucleotides of the invention comprise a coding sequence encoding a polypeptide having one or more of the functional properties of MGF, as defined herein, which coding sequence is selected from:
• the invention provides polynucleotides comprising the coding sequence as shown in any one of SEQ ID NO. 1, 3 or 5 and variants thereof with related sequences. Polynucleotides of the invention can be used to prepare vectors of the invention.
• Preferred polynucleotides of the invention comprise coding sequences as shown in SEQ ID NOs. 1, 3 and 5.
• a polynucleotide of the invention may hybridise selectively to coding sequence of SEQ ID NO. 1, 3 or 5 at a level significantly above background. Background hybridisation may occur, for example because of other cDNAs present in a cDNA library.
• the signal level generated by the interaction between a polynucleotide of the invention and the coding sequence of SEQ ID NO. 1, 3, 5, 1, 9 or 11 is typically at least 10 fold, preferably at least 100 fold, as intense as interactions between other polynucleotides and the coding sequence of SEQ ID NO. 1, 3 or 5.
• the intensity of interaction may be measured, for example by radiolabelling the probe, e.g. with 32 P.
• Selective hybridisation is typically achieved using conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C, for example 45 to 50, 50 to 55 or 55 to 60°C, e.g. at 50 or 60°C.
• medium to high stringency for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C, for example 45 to 50, 50 to 55 or 55 to 60°C, e.g. at 50 or 60°C.
• hybridisation may be carried out under any suitable conditions known in the art (see Sambrook et al, 1989, Molecular Cloning: A Laboratory Manual).
• suitable conditions include 0.2 x SSC at around 60°C, for example 40 to 50°C, 50 to 60°C or 60 to 70°C, e.g. at 50 or 60°C.
• suitable conditions include 2 x SSC at around 60°C, for example 40 to 50°C, 50 to 60°C or 60 to 70°C, e.g. at 50 or 60°C.
• a hybridisable sequence may be one which hybridises to SEQ ID NO. 1, 3 or 5 at a temperature of from Tm to Tm-25°C, e.g. Tm to Tm-5°C, Tm-5 to Tm-10°C, Tm-10 to Tm-20°C or Tm-20 to Tm-25°C.
• a polynucleotide sequence of the invention will comprise a coding sequence at least 70% preferably at least 80 or 90% and more preferably at least 95, 98 or 99%, homologous to the coding sequence of SEQ ID NO. 1, 3 or 5. Such homology will preferably apply over a region of at least 20, preferably at least 50, for instance 100 to 500 or more, contiguous nucleotides.
• nucleic acid and polypeptide homology are well known in the art. These methods can be applied to measurement of homology for both polypeptides and nucleic acids of the invention.
• UWGCG Package provides the BESTFIT program which can be used to calculate homology (Devereux et al, 1984, Nucleic Acids Research 12, p.387-395).
• PILEUP and BLAST algorithms can be used to line up sequences (for example as described in Altschul, S.F., 1993, J Mol. Evol. 30:290-300; Altschul, S.F. et al, 1990) J. Mol. Biol. 215:403-410).
• the default settings may be used.
• the BLAST algorithm is suitable for determining sequence similarity and it is described in Altschul et al (1990) J Mol. Biol. 215:403-410.
• Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi/nlm.hih.gov/).
• This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold (Altschul et al, supra).
• HSPs high scoring sequence pair
• T is referred to as the neighbourhood word score threshold (Altschul et al, supra).
• These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them.
• the word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached.
• the BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment.
• the BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g. Karlin and Altschul (1993) Proc. Natl. Sci. USA 90:5873-5787.
• One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance.
• P(N) the smallest sum probability
• a nucleic acid is considered similar to a fused gene or cDNA if the smallest sum probability in comparison of the test nucleic acid to a fused nucleic acid is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.
• sequences which are fragments of the sequences of (a) to (d) above but which encode MGF polypeptides having the properties discussed herein.
• fragments may comprise exons 5 and 6 or 4, 5 and 6 or exons 3, 4, 5 and 6 of human, rat or rabbit MGF DNA of SEQ ID NO. 1, 3 or 5.
• the first amino acid of exon 4, Asn is partly encoded by exon 3 and partly by exon 4. It is preferred that the necessary coding bases from exon 3 are present to encode said first amino acid, Asn. Degenerate sequences
• the invention provides degenerate variants of the sequence of SEQ ID NOs. 1, 3 and 5 that also encode the polypeptide of SEQ ID NOs. 2, 4 and 6.
• the invention provides polynucleotides having sequences complementary to any of the above-mentioned sequences.
• Chimeric sequences comprising exons from more than one species may also be used.
• one or more of exons 3 to 6 may be derived from human and one or more from rat and/or rabbit.
• nucleic sequences of the invention may be of any length as long as they encode a polypeptide of the invention.
• a nucleic acid sequence according to the invention may be a contiguous fragment of the sequence of SEQ ID NO. 1, 3 or 5 or a sequence that is related to it in any of the ways described above.
• nucleic acids of the invention may comprise DNA sequences that are not contiguous in the sequence of SEQ ID NO. 1, 3 or 5. These sequences may be fragments of the sequence of SEQ ID NO. 1, 3 or 5 or nucleic acid sequences that are related to such fragments in any of the ways described above.
• Nucleic acid sequences of the invention will preferably comprise at least 50 bases or base pairs, for example 50 to 100, 100 to 500, 500 to 1000 or 1000 to 2000 bases or base pairs.
• any combination of the above-mentioned degrees of homology and minimum sizes may be used to defined polynucleotides of the invention, with the more stringent combinations (e.g. higher homology over longer lengths and/or hybridisation under more stringent conditions)being preferred.
• a polynucleotide which is at least 90%> homologous over 100 nucleotides forms one aspect of the invention, as does a polynucleotide which is at least 95% homologous over 100 or 200 nucleotides.
• Polynucleotides of the invention may comprise DNA or RNA. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to polynucleotides are known in the art. Modifications may, for example enhance resistance to nucleases and/or enhance ability to enter cells. For example, phosphorothioate oligonucleotides may be used.
• deoxynucleotide analogs include methylphosphonates, phosphoramidates, phosphorodithioates, N3'P5'-phosphoramidates and oligoribonucleotide phosphorothioates and their 2'-O-alkyl analogs and 2'-O-methyliribonucleotide methylphosphonates.
• a further possible modification is the addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule.
• MBOs Mixed backbone oligonucleotides
• MBOs contain segments of phosphothioate oligodeoxynucleotides and appropriately placed segments of modified oligodeoxy- or oligoribonucleotides.
• MBOs have segments of phosphorothioate linkages and other segments of other modified oligonucleotides, such as methylphosphonate, which is non-ionic, and very resistant to nucleases or 2'-O-alkyloliogoribonucleotides.
• methylphosphonate which is non-ionic, and very resistant to nucleases or 2'-O-alkyloliogoribonucleotides.
• the polynucleotides described herein may be modified by any method available in the art.
• Polynucleotides of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe, e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors.
• a primer e.g. a PCR primer, a primer for an alternative amplification reaction, a probe, e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors.
• primers, probes and other fragments will preferably be at least 10, preferably at least 15 or 20, for example at least 25, 30 or 40 nucleotides in length. These will be useful in identifying species homologues and allelic variants as discussed above.
• Polynucleotides such as a DNA polynucleotides and primers according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques. The polynucleotides are typically provided in isolated and/or purified form.
• primers will be produced by synthetic means, involving a stepwise manufacture of the desired nucleic acid sequence one nucleotide at a time.
• Genomic clones corresponding to the cDNAs of SEQ ID NOs. 1, 3 and 5 containing, for example introns and promoter regions are also aspects of the invention and may also be produced using recombinant means, for example using PCR (polymerase chain reaction) cloning techniques.
• the 4-5-6 exon pattern of MGF is characteristic of polynucleotides of the invention. Any suitable method may be used to ensure that this pattern is reflected in the coding sequence, and thus in the encoded polypeptide.
• cDNA sequences lacking introns and splice signals and including the coding sequences of exons 4, 5 and 6 may be used.
• genomic DNA may be used if it will be correctly spliced in the situation at hand.
• Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention, as described above, can be obtained in a number of ways, for example by probing cDNA or genomic libraries from other plant species with probes derived from SEQ ID NO. 1, 3 or 5.
• Degenerate probes can be prepared by means known in the art to take into account the possibility of degenerate variation between the DNA sequences of SEQ ID NO. 1, 3 or 5 and the sequences being probed for under conditions of medium to high stringency (for example 0.03M sodium chloride and 0.03M sodium citrate at from about 50°C to about 60°C), or other suitable conditions (e.g. as described above).
• Allelic variants and species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding likely conserved amino acid sequences.
• Likely conserved sequences can be predicted from aligning the amino acid sequences of the invention (SEQ ID NO. 2, 4 or 6) with each other and/or with those of any homologous sequences known in the art.
• the primers will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.
• polynucleotides may be obtained by site-directed mutagenesis of sequences of SEQ ID NO. 1, 3 or 5 or allelic variants thereof. This may be useful where, for example silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequences may be desired in order to introduce restriction enzyme recognition sites, or to alter the properties or function of the polypeptides encoded by the polynucleotides.
• the invention further provides double stranded polynucleotides comprising a polynucleotide of the invention and its complement.
• Polynucleotides, probes or primers of the invention may carry a revealing label.
• Suitable labels include radiosotopes such as 32 P or 35 S, enzyme labels, or other protein labels such as biotin. Such labels may be added to polynucleotides, probes or primers of the invention and may be detected using techniques known per se.
• Ischemia occurs when an artery supplying oxygenated blood to a muscle or other organ becomes occluded. This diminishes the ability of the affected organ to function and may involve cell death in the area whose blood supply is reduced.
• ischemia can result from an obstruction of the coronary arteries. This leads to cardiomyocytes in certain areas becoming deprived of blood and thus oxygen. They then commence to die.
• MGF polypeptides can be delivered to subjects in need of treatment by any suitable method. Generally, MGF polypeptides will be delivered intravenously as this is a safe and reliable method of delivery. Under appropriate clinical circumstances (e.g. in specialist cardiac units) direct delivery to the heart may also be possible, e.g. using a so-called “needle-less" injection system (e.g. provided by Powderject) to deliver the polypeptide to the heart.
• a so-called “needle-less" injection system e.g. provided by Powderject
• the MGF polypeptide will be administered as rapidly as possible after the onset of the ischemia or mechanical overload to the heart, for example as soon as a heart attack resulting from ischemia has been diagnosed. Preferably, it will be administered within 5, 10, 15, 30 or 60 minutes, or within 2 or 5 hours. Long term treatment can also be effected by re-administration of the polypeptide, but delivery of an MGF-encoding polynucleotide is preferred for that purpose (see below).
• the ischemia or mechanical overload in response to which the MGF polypeptide or polynucleotide is administered is a temporary condition.
• the MGF polypeptide is administered in response to a heart attack.
• Treatments of the invention will be particularly effective in helping heart attack sufferers make a good recovery; and to return to a normal, active lifestyle.
• MGF polypeptides may be produced in any suitable manner. In some embodiments they may be extracted from animal tissues. However, it is preferred that they be produced recombinantly. This can be done using known techniques. TJse of MGF polynucleotides in addition to MGF polypeptides
• a polynucleotide encoding an MGF polypeptide of the invention may be delivered a well as the MGF polypeptide.
• MGF polypeptide-encoding may be delivered simultaneously with the polypeptide or separately. It may be delivered in the same pharmaceutical formulation or a different one and by the same route of administration or a different one.
• MGF has a short half-life and in vivo expression of MGF facilitates localisation and avoids the need for repeated injection to effect long- term therapy. Intramuscular administration is preferred for polynucleotides of the invention, especially plasmids and other naked nucleic acids.
• the polynucleotides of the invention may be delivered in any suitable manner.
• they will generally be delivered via a vector.
• Any suitable vector may be used.
• the polynucleotide may be delivered in a "naked" form (e.g. in a plasmid vector), optionally associated with an agent to assist in its penetration, as discussed below.
• the vector may be one that encapsulates the nucleic acid, e.g. a virus.
• the vector may, for example, be a plasmid or cosmid vector, or another type of vector.
• the vector may be a viral vector, such as a vector comprising a virus able to infect the cells of the recipient subject.
• the vector may be, or may be derived from any suitable virus, for example an alphavirus, adenovirus, adeno-associated virus, baculovirus, vaccinia virus, herpes virus, herpes simplex virus, retrovirus (e.g. lentivirus) vector, or baculovirus.
• a virus vector will be disabled, in the sense that it will not typically be able to replicate or cause pathological effects in the same way as on intact virus. It will typically be attenuated, for example replication defective.
• the polynucleotide may be associated with an agent to assist in penetration of cells.
• agents include cationic agents (e.g. cationic lipids), polylysine, lipids, and precipitating agents (e.g. a calcium salt).
• agents generally aid the passage of the polynucleotide across the cell membrane.
• the polynucleotide may be in the form of liposomes or particles, for example in association with any of the penetrating agents mentioned above.
• the polynucleotide may be in association with an agent that causes the polynucleotide to adopt a more compact form, such as a histone.
• the polynucleotide may be in association with spermidine.
• liposomes may be used to help transport polynucleotides of the invention into cells.
• the polynucleotide may be associated with a carrier which can be used to deliver the polynucleotide into the cell, or even into the nucleus, using biolistic techniques.
• a carrier may be a metal particle, such as a gold or tungsten particle.
• the polynucleotide is typically capable of being expressed in a cell of the recipient.
• the polynucleotide typically also comprises control sequences which are operably linked to the MGF coding sequence of the invention, said control sequences being capable of expressing the coding sequence in the cells of the recipient, for example after integration of the polynucleotide into the genome of the cell.
• the control sequences typically comprise a promoter (generally 5' to the coding sequence) and/or a terminator and/or translation initiation sequence (e.g. GCCACCATGG (SEQ ID NO. 7) or GCCCCCATGG (SEQ ID NO. 8)) and/or a translational stop codon (e.g. TAA, TAG or TGA) and/or a polyadenylation signal and/or one or more enhancer sequences and/or a RNA pause site.
• the control sequences may enhance the transcription or translation of the polynucleotide.
• the control sequences may be tissue-specific so that the polynucleotide is only expressed in certain tissues, or may be the control sequences of a constitutively expressed gene.
• Muscle-specific promoters and enhancers are particularly preferred.
• the control sequences are typically those of any of the eukaryotes mentioned herein or of a virus which infects a eukaryote, e.g. of the species of the recipient, such as a human virus for a human recipient.
• the polynucleotide may comprise an origin of replication.
• the promoter may, for example be (in particular for expression in mammalian cells) a metallothionein gene promoter, SN40 large T antigen promoter, CMN or adenoviral promoter.
• muscle-specific control elements such as muscle-specific promoters and enhancers, are particularly preferred, especially where the nucleic acid is to be delivered intramuscularly, e.g. in plasmid form.
• Such elements can be derived from, for example myosin genes.
• myosin light chain or heavy chain promoters may be used, as may myosin light chain or heavy chain enhancers.
• myosin enhancers and promoters have been identified to date from both myosin light chain and myosin heavy chain genes.
• the myosin enhancer and/or promoter used is of vertebrate origin, more preferably avian, piscine or mammalian origin.
• a myosin light chain enhancer is preferred.
• a rat myosin light chain 1/3 enhancer (Donoghue et al (1988) Genes Dev. 2: 1779-1790; Neville et al (1996) Dev. Genetics 19: 157-162) is especially preferred.
• the enhancer is operably linked to the promoter.
• the enhancer may be either upstream or downstream of the promoter.
• the enhancer may be used in either orientation.
• a myosin heavy chain promoter is preferred.
• a particularly preferred myosin heavy chain promoter is a truncated rabbit ⁇ -cardiac myosin heavy chain promoter, in particular up to and including 789 base pairs upstream of the trans criptional start site.
• myosin heavy chain promoter is the carp FG2 promoter, in particular up to and including 901 base pairs upstream of the transcription start site (Gauvry et al (1996) Eur. J. Biochem. 236:887-894). Further details of myosin heavy chain promoters derived from rat, rabbit, human, porcine and chick myosin heavy chain genes are given in Gauvry et al (1996) and references therein. All of these promoters may be used in the present invention.
• any suitable regulatory elements may be used, and the ones mentioned above are merely exemplary.
• introduction of MGF of the invention may be linked with physical activity.
• myosin is the most abundant protein in muscle the myosin promoter/enhancer regulatory elements means that the expression of the cDNA will be upregulated by increased muscular activity.
• Plasmid vectors and disabled viral vectors are preferred embodiments. Plasmid vectors are particularly preferred, especially for intramuscular administration aimed at securing local expression in the muscle.
• the vector may be designed for stable integration into the genome of the recipient's cells. Alternatively, it may be designed to be non-integrative. In stable introduction the polynucleotide becomes integrated into the genome of the cell (i.e. becomes contiguous with genome). Thus, the polynucleotide may also comprise a sequence which enhances integration of the polynucleotide such as the loxP sites of the bacteriophage PI Cre recombination system, FRT sites of the yeast FLP recombination system or Adeno-associated virus (AAV) terminal repeat sequences.
• AAV Adeno-associated virus
• Integration may be enhanced by other factors which are present, such as bacteriophage PI derived Cre, yeast derived FLP recombinase, AANRep proteins, Cre or FLP recombinases or bacterial Rec proteins.
• the polynucleotide of the invention is capable of expressing such a factor.
• the polynucleotide may be one which integrates randomly (such as in a non- sequence specific manner) into any position in the genome or one which preferentially integrates at particular sites of the genome. Generally the whole coding sequence of the polynucleotide and the control sequences will be present in the genome after integration.
• polypeptides and polynucleotides of the invention are preferably delivered in the form of a pharmaceutical formulation comprising a pharmaceutically acceptable carrier or diluent. Any suitable pharmaceutical formulation may be used.
• suitable formulations may include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, bactericidal antibiotics and solutes which render the formulation isotonic with the bodily fluids of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
• the formulations may be presented in unit-dose or multi-dose containers. For example, sealed ampoules and vials, and may be stored in a frozen or freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
• formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question.
• Sterile, pyrogen-free aqueous and non-aqueous solutions are preferred.
• the proteins, polynucleotides and vectors of the invention may be delivered in any suitable dosage, and using any suitable dosage regime.
• Persons of skill in the art will appreciate that the dosage amount and regime may be adapted to ensure optimal treatment of the particular condition to be treated, depending on numerous factors. Some such factors may be the age, sex and clinical condition of the subject to be treated.
• the dosage used for the delivery of nucleic acids by vectors will depend on many factors, including the efficiency with which the vectors deliver the nucleic acids to cells, and the efficiency with which the nucleic acids are expressed in the cells.
• typical doses are from 0.1 to 5000 ⁇ g, for example 10 to lOOO ⁇ g, such as 10 to lOO ⁇ g, 100 to 500 ⁇ g and 500 to 2000 ⁇ g per dose.
• viral vectors may be delivered in doses of from 10 4 to 10 14 cfu or pfu/ml, for example 10 4 to 10 6 , 10 6 to 10 8 , 10 8 to 10 10 , 10 10 to 10 12 or 10 12 to 10 14 cfu or pfu/ml. Doses in the region of 10 s to 10 9 cfu or pfu/ml are preferred.
• pfu plaque forming unit
• viruses including adenoviruses, and corresponds to the infectivity of a virus solution, and is determined by infection of an appropriate cell culture, and measurement, generally after 48 hours, of the number of plaques of infected cells.
• cfu colony forming unit
• cfu colony forming unit
• the term for determining the cfu or pfu titre of a viral solution are well known in the art.
• dosages in the region of 10 s to 10 6 cfu/ml are particularly preferred.
• dosages in the region of 10 7 cfu/ml are particularly preferred.
• dosages in the region of 10 9 pfu/ml are particularly preferred.
• suitable doses include doses of from 1 to lOOO ⁇ g, from 10 to lOO ⁇ g, from 100 to 500 ⁇ g and from 500 to lOOO ⁇ g.
• Dosage schedules will also vary according to, for example the route of administration, the species of the recipient and the condition of the recipient.
• MGF polypeptide will typically be given rapidly after the ischemic incident overload, or mechanical as discussed above.
• further doses may be spread over periods of, e.g. days, weeks or months.
• delivery by means of polynucleotides that are expressed in vivo is advantageous for long term treatment because it minimises the need for injections into the subject.
• Example 1 Induction of MGF expression in vivo during functional ischemia and overload
• RT-PCR reverse transcriptase PCR
• ANF is an embryonic marker gene that is up regulated in hypertrophic conditions. It can be seen that the banding induced ANF expression indicating cardiac hypertrophy in this model. Also, Bax gene expression is up regulated during apoptosis and in pathological situations and this did not occur in the aortic-banded mice by 7 days. This data shows that MGF expression is increased by functional overload and that, in contrast to the situation for liver-type IGF-I, this expression coincides with the immediate recovery stage after overload. We detected similar changes just following transient ischemia in the rat and the sheep and the expression of MGF was found to be high near to the area of the infarct where the cardiomyocytes are subjected to mechanical overload (see below).
• Example 2 Overexpression of MGF in vitro in primary cardiac myocytes
• MGF expression in primary myocardiocytes was achieved by transfecting a plasmid containing the MGF cDNA into primary cultures of cardiac myocytes prepared from neonatal mice (Goldspink et al (1997)).
• the initial assay following the transfection was to determine whether there was a change in the number of cells.
• Myocytes are terminally differentiated cells that do not undergo cell division once committed to myocyte lineage.
• An increase in the number of cells could account for increases in gene expression that were to be assayed and thereby suggest that MGF may not be involved in cardiac hypertrophy.
• Unlike the situation in skeletal muscle there was no increase in the number of cells in any of the conditions following transfection. Therefore it can be concluded that the role of MGF in the myocardium is not principally to induce cell division.
• Increased expression of MGF without a corresponding increase in L.IGF-I expression, shows that it is the MGF isoform that is induced under apoptotic conditions.
• phorbol myristate acetate a phorbol ester that specifically activates the Protein Kinase C family of serme/threonine signaling kinases.
• PMA phorbol myristate acetate
• Figure 4 a brief exposure to PMA (200 nM), brings about a significant increase in the expression of the endogenous MGF gene.
• cardiac myocytes were cultured in the presence of sorbitol. This places the cells under osmotic stress which causes them to swell and eventually die. Initially, myocytes were cultured in defined media minus serum for 24 hours before the addition of sorbitol. Following exposure to sorbitol, RNA was extracted and gene expression was assayed with real time RT-PCR. Shown in Figure 5 are the changes in MGF and IGF-I gene expression after a short exposure (4 hours) to sorbitol. The expression of MGF can be initially seen to increase whereas IGF does not change.
• MGF expression is the same as control whereas IGF is increased. This demonstrates the different kinetics of MGF as compared to IGF-I, and further supports the idea that it is MGF expression that is decisive following ischemia/mechanical overload. Increased Bax gene expression also indicated that the cells are undergoing apoptosis, which was further demonstrated by the appearance of DNA fragmentation in the sorbitol treated cultures after 24 hours.
• a cardiac-like cell line (H9C2) (Kimes et al (1976), and commercially available from American Type Culture Collection PO Box 1549, Manassas, Virginia 20108, USA) was stably transfected with MGF and liver-type IGF cDNA using a pcDNA3.1/NT-GFP vector (Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008, USA) and the techniques of Southern et al (1982). The stably transfected cell lines plus the non-transfected control were then treated with sorbitol for 24 hours and DNA extracted to analyze the extent of DNA fragmentation, which is an indicator of apoptosis.
• H9C2 cardiac-like cell line
• Example 5 Evidence that MGF and L.IGF-I peptides accumulate differently within cardiomyocytes
• This vector carries the homology regions for the homologous recombination with the pAdEasy vector, which is derived from the human adenovirus serotype 5.
• the virus is rendered replication deficient by deletion of the packaging and host immunity genes ( El and E3).
• the resulting viral/vector construct was used to transfect 293 packaging cells to produce a primary viral stock.
• the primary stock was used to amplify the virus through a series of infections in 293 cells before the final viral stock was purified by CsCl ultra centrifugation.
• the final viral titer was quantified via a spectrophotometric method, which yielded a purified viral titer in the order of 10 n -10 12 particles/ml. These particles were used to infect primary myocytes in the range of 10 8 -10 9 particles /ml.
• virus cells were counter stained with dia (DAPI), which binds to chromatin in the nucleus and can be viewed with fluorescence. Shown in Figure 15 are the results of the staining. The pattern of staining confirms MGF expression in the nucleus.
• DAPI dia
• myocytes were infected for longer periods to determine the effects of MGF over expression.
• Cells were plated and infected with the MGF virus and a GFP expressing virus as a control for 48hrs.
• Following infection cells were fixed in paraformaldehyde and counter stained with Texas Red conjugated phalloidin (Molecular Probes) to visualize the myofilaments and DAPI to visualize the nucleus.
• Shown in Figure 16 are the results of a 48 -hour infection. In the control myocytes without infection the presence of striated myofilaments can be seen with the phalloidin stain ( Figure 16A).
• FIG 17 Shown in Figure 17 are the results following electrophoresis of the thick filament proteins (myosin heavy chain and light chains) and the thin filament proteins (actin, tropomyosin and troponin T).
• a down regulation of the thick filament proteins can be clearly seen in the MGF infected cells, whereas the thin filament proteins do not appear to be affected.
• Four separate cultures were used as controls without infection and four separation cultures infected with the MGF virus.
• MGF and L.IGF-I have different expression kinetics. Muscle damage was induced by mechanical means and via a myotoxic agent. The results clearly showed that MGF is produced shortly after the insult whereas L. IGF- IEa was expressed several days later.
• Muscle damage was induced by mechanical means, namely stretch and stimulation, and inj ection of the myotoxic agent bupivacaine.
• Figure 20 shows the results of investigation of mRNA levels of MGF and IGF-IEa isoforms in the two models of muscle damage.
• MGF was maximally expressed as early as 1 day following stretch and stimulation and 4 days following bupivacaine injection ( Figure 20 A), whereas liver-type IGF-IEa was maximally expressed later at 7 and 11 days following injury ( Figure 20B).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Gastroenterology & Hepatology (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Immunology (AREA)
• Zoology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Hospice & Palliative Care (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Related Child Applications (3)

Publications (1)

Family

ID=9930632

Family Applications (1)

Country Status (9)

Cited By (5)

Families Citing this family (2)

Citations (1)

Family Cites Families (28)

• 2002
  • 2002-02-07 GB GBGB0202906.4A patent/GB0202906D0/en not_active Ceased
• 2003
  • 2003-02-06 JP JP2003565505A patent/JP2005516997A/ja active Pending
  • 2003-02-06 EP EP03737378A patent/EP1480669B1/en not_active Expired - Lifetime
  • 2003-02-06 AU AU2003244511A patent/AU2003244511A1/en not_active Abandoned
  • 2003-02-06 WO PCT/GB2003/000537 patent/WO2003066082A1/en not_active Ceased
  • 2003-02-06 DK DK03737378.4T patent/DK1480669T3/da active
  • 2003-02-06 ES ES03737378T patent/ES2432082T3/es not_active Expired - Lifetime
  • 2003-02-06 PT PT37373784T patent/PT1480669E/pt unknown
  • 2003-02-06 US US10/504,078 patent/US20050048028A1/en not_active Abandoned
• 2007
  • 2007-03-20 US US11/723,493 patent/US20080039390A1/en not_active Abandoned
• 2012
  • 2012-09-21 US US13/624,365 patent/US9919031B2/en not_active Expired - Fee Related
• 2018
  • 2018-03-13 US US15/920,361 patent/US20180271942A1/en not_active Abandoned

Patent Citations (1)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events